Dociparstat sodium
CMX-DS-004
Phase 3 small_molecule terminated
Quick answer
Dociparstat sodium for Coronavirus Disease 2019 (COVID-19) is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- Coronavirus Disease 2019 (COVID-19)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated